随着辉瑞公司(pfizer)加巴喷丁(gabapentin,neurontin)非专利药的上市,其在美国神经性疼痛药物市场的销售将受到严重影响。辉瑞公司为了稳固自身地位,积极开发新产品普瑞巴林(pregabalin,lyrica)。 本品最常见的不良反应有眩晕、嗜睡等。 然而由于动物模型中存在的安全性问题,fda的审批严重延后。新的临床研究进一步肯定了本品治疗神经性疼痛的疗效,有助于加快fda的审批进程。 Mechanism of Action LYRICA (pregabalin) binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in pregabalin's antinociceptive and antiseizure effects in animal models. In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function. While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABAA, GABAB, or benzodiazepine receptors, does not augment GABAA responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport. Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.
今年5月份,一种新型药物能够治疗慢性疲劳、肌肉疼痛和纤维肌痛,这就是由美国辉瑞药业研制的“Lyrica”,目前美国食品卫生管理局已对该药审批通过。据了解,美国大约有300-600万名纤维肌痛症患者,其中多数是女性,由于这种疾病很复杂,普通的止痛药对此病无能为力,之前也没有针对性的药物治疗。纤维肌痛症是最常见的慢性周身疼痛疾病,常伴有失眠和僵硬,严重时导致劳动力丧失。 |
当前位置:药品说明书与价格首页 >> 综合药讯 >> LYRICA(普瑞巴林胶囊,pregabalin)-治疗纤维肌痛症新药
LYRICA(普瑞巴林胶囊,pregabalin)-治疗纤维肌痛症新药简介:
随着辉瑞公司(pfizer)加巴喷丁(gabapentin,neurontin)非专利药的上市,其在美国神经性疼痛药物市场的销售将受到严重影响。辉瑞公司为了稳固自身地位,积极开发新产品普瑞巴林(pregabalin,lyrica ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多
|